[Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].

Orv Hetil

Semmelweis Egyetem, Altalános Orvostudományi Kar, I. Gyermekgyógyászati Klinika, Budapest.

Published: October 2009

Treatment with the chimeric monoclonal antibody (infliximab) is highly effective in refractory and fistulising Crohn's disease, nevertheless, infliximab resistance may occur. Authors report a 12-year-old boy with infliximab refractory luminal Crohn's disease including 3 active perianal fistulas. The patient was treated successfully with adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody. After 10 weeks of therapy, the previously high activity index returned to normal and the fistulas were closed. Quality of life using validated questionnaire improved significantly also. Adalimumab might be a suitable therapy even in pediatric Crohn's disease patients with infliximab resistance.

Download full-text PDF

Source
http://dx.doi.org/10.1556/OH.2009.28731DOI Listing

Publication Analysis

Top Keywords

crohn's disease
12
monoclonal antibody
8
infliximab resistance
8
[adalimumab treatment
4
treatment infliximab-resistant
4
infliximab-resistant pediatric
4
pediatric patient
4
crohn's
4
patient crohn's
4
crohn's disease]
4

Similar Publications

Paratuberculosis is an infectious disease caused by subspecies (MAP). Typically, ruminant animals including cattle, buffalo, goats, and sheep are infected with MAP. Animals get infected with MAP in a number of ways, such as by eating or drinking contaminated food or water, or by nursing from an infected mother who may have contaminated teats or directly shed the organism in milk or colostrum.

View Article and Find Full Text PDF

Objectives: This study evaluated the clinical utility of the Patient-Reported Outcomes Measurement Information System (PROMIS) by comparing it with objective clinical data and validated health-related quality of life (HRQOL) measures in pediatric Crohn's disease (CD) patients.

Study Design: Cross-sectional study. Pediatric CD patients (aged 8-17 years) were enrolled prospectively over eight months from an outpatient pediatric gastroenterology center.

View Article and Find Full Text PDF

Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease.

BMC Gastroenterol

December 2024

Formerly Gastroenterology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clínic de Barcelona, Barcelona, Spain.

Background: Current therapies for complex Crohn's perianal fistulas (CPF) have a limited ability to achieve long-term healing. Darvadstrocel (DVS) is an expanded allogeneic adipose-derived mesenchymal stem cell therapy that has demonstrated efficacy in treating complex CPF in clinical trials. There are, however, limited long-term comparative data with standard of care (SoC).

View Article and Find Full Text PDF

Background: With 20-40% of patients who have inflammatory bowel disease (IBD) not responding to therapy, resource use and costs can be high. We performed a descriptive analysis of health-care data for IBD management in the National Health Service to explore potential areas for improvement.

Methods: In this exploratory study, we analysed real-world data from the Discover dataset for adults with a diagnosis of incident IBD recorded in northwest London, UK, between 31 March, 2016, and 31 March, 2020.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!